IOVA vs NTRA
Iovance Biotherapeutics, Inc. vs Natera, Inc. — AI-powered side-by-side comparison
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
VS
| Metric | IOVA | NTRA |
|---|
| AI Score |
67
|
67
|
| Price |
$6.99
|
$309.83
|
| P/E Ratio |
-9.31×
|
-228.51×
|
| ROE |
-56.0%
|
-12.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
116.3%
|
65.3%
|
| Debt / Equity |
0.06×
|
0.13×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
73.2
|
66.7
|
| Beta |
0.701
|
1.514
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for IOVA versus NTRA.
The committee scores are tied.
IOVA and NTRA both score 67/100.
IOVA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 73 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
NTRA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 37.8% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Price-to-book of 18.5x prices in significant intangible value — Value
- ROE of only -11.7% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 33.7% signals elevated volatility — Risk